BioRad Laboratories: Genprex Advances Gene Therapy at BIO Europe Spring Conference 2025
- Genprex will showcase its innovative gene therapy at the BIO Europe Spring conference in Milan, March 2025.
- The Oncoprex® Delivery System delivers gene-expressing plasmids to tumor cells, offering a novel cancer treatment approach.
- Genprex is developing diabetes gene therapy to convert alpha cells to insulin-producing cells, addressing critical health needs.
Genprex's Commitment to Gene Therapy Innovation
Genprex, Inc., a clinical-stage gene therapy company, prepares for a significant presence at the upcoming BIO Europe Spring conference, taking place from March 17-19, 2025, in Milan, Italy. With over 3,700 industry executives expected to attend, Genprex’s leadership, including President and CEO Ryan Confer, aims to showcase its groundbreaking work in gene therapy. The conference serves as a vital platform for Genprex to engage in personalized discussions with stakeholders across the biotech, pharmaceutical, and finance sectors, emphasizing its mission to deliver transformative treatments for patients suffering from cancer and diabetes. The company’s strategic participation underscores its commitment to advancing innovative therapies in these critical areas of healthcare.
At the core of Genprex's therapeutic offerings is the Oncoprex® Delivery System, which utilizes lipid-based nanoparticles designed to deliver gene-expressing plasmids directly to tumor cells. This innovative delivery method promotes the expression of tumor suppressor proteins, providing a novel approach to cancer treatment. Genprex’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently undergoing evaluation in two pivotal clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both programs have received Fast Track Designation from the FDA, with the SCLC program also granted Orphan Drug Designation, reflecting the urgent need for effective therapies in these challenging cancer types.
In addition to its oncology initiatives, Genprex is making strides in diabetes treatment through its innovative gene therapy approach. The company is developing a diabetes gene therapy utilizing an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. In preclinical models of Type 1 diabetes, Genprex’s candidate GPX-002 has demonstrated promise in converting alpha cells into insulin-producing beta-like cells. For Type 2 diabetes, the therapy aims to rejuvenate exhausted beta cells, addressing a major unmet medical need. This dual focus on oncology and diabetes positions Genprex as a leader in the gene therapy landscape, targeting critical health challenges with the potential for life-changing outcomes.
Looking Ahead to BIO Europe Spring
As Genprex prepares for BIO Europe Spring, the company's innovative approaches to gene therapy continue to attract attention within the biotech community. The upcoming event not only provides an opportunity for networking but also allows Genprex to highlight its commitment to developing solutions for patients with limited treatment options.
Through its pioneering research and collaborations, Genprex is poised to make significant contributions to gene therapy, reinforcing its role as a key player in the biopharmaceutical industry.